Anteris Technologies (AVR) Registration filing summary

Company overview and business model

• Focuses on developing and commercializing innovative medical devices for aortic stenosis, with DurAVR® THV as the lead product, leveraging proprietary ADAPT® anti-calcification tissue technology and the ComASUR® delivery system.

• Operations are being reorganized from an Australian entity to a Delaware corporation, with a NASDAQ listing and concurrent ASX CDI listing.

• The company is in the development stage, with limited revenue from legacy tissue products and ongoing investment in R&D and clinical trials.

• Strategic collaborations include a 30% stake and development agreement with v2vmedtech for mitral and tricuspid valve repair devices.

Financial performance and metrics

• Net sales were $2.2M for the nine months ended September 30, 2024, down 1% year-over-year; annual net sales for 2023 were $2.7M, down 15% from 2022.

• Operating losses were $57.3M for the nine months ended September 30, 2024, and $48.1M for the year ended December 31, 2023.

• Accumulated deficit reached $257.0M as of September 30, 2024.

• Cash and cash equivalents were $10.6M as of September 30, 2024, with negative cash flows from operations of $43.0M for the first nine months of 2024.

• The company has a history of recurring losses and negative cash flows, with a going concern warning from auditors.

Use of proceeds and capital allocation

• Net proceeds of $90.6M (or $104.5M if underwriters' option is exercised) are expected, assuming a $6.78/share IPO price.

• Approximately $74.4M will be allocated to ongoing development of DurAVR® THV and the pivotal clinical trial; the remainder will be used for working capital, general corporate purposes, and repayment of convertible note facility.

• Proceeds are not sufficient to fund DurAVR® THV through regulatory approval; additional capital will be required.